Centre National De La Recherche Scientifique

Université De Nantes

Institut National De La Sante Et De La Recherche Medicale

Chu Nantes

Université Du Mans

Institut National De La Sante Et De La Recherche Medicale (inserm)

Nantes Université

Jacques Lebreton

Agnès Quemener

Muriel Pipelier

Vincent Sauzeau

Gervaise Loirand

Arnaud Tessier

Maxim Egorov

Dominique Heymann

Monique Mathé

Jacques Le Pendu

Francoise Redini

Marc Padrines

Agnes Quemenier

Fabrice Fleury

Alexandre Demeyer

Pierre Weigel

Benoit Chenais

Yannick Fortun

Didier Dubreuil

Allan Patinec

Agnès Quemenier

Françoise Redini

Compounds of general formula: wherein Rand Rare independently selected from hydrogen and pharmaceutically acceptable cations; and Rand Rare identical and selected from amide, carbamate, sulphonamide, azido, cyano and halide. Also, a pharmaceutical composition including one of the compounds. The composition may also include another active ingredient, especially an antineoplastic agent. Further a compound or a composition for use as a medicament, especially a compound or a composition for use in the treatment of a proliferative disease such as for example cancer.

Disulfonate stilbenes for use in the treatment of proliferative diseases

The present invention concerns a compound having the following formula (I): wherein:

Inhibitors of RAC1 and uses thereof for treating cancers

The present invention concerns a compound having the following formula (I): wherein: &#x2014;A is in particular &#x2014;N(R')&#x2014;C(&#x2550;O)&#x2014;R, R&#x2032;being H or a (C-C)alkyl group, and R being preferably a group having the following formula (II): &#x2014;X is in particular chosen from the group consisting of: &#x2014;SO&#x2014;N(R&#x2032;)&#x2014;, R&#x2032;being H or a (C-C)alkyl group, &#x2014;N(R&#x2033;)&#x2014;SO&#x2014;, R&#x2033;b being H or a (C-C)alkyl group, &#x2014;CO&#x2014;NH&#x2014;, and &#x2014;NH&#x2014;CO&#x2014;, for use for the treatment of pathologies characterized by bronchoconstriction, such as asthma. 

Inhibitors of RAC1 and uses thereof for inducing bronchodilatation

The present invention relates to hydroxy-bisphosphonic acid derivatives corresponding to general formula (I): in which: -n and m denote, independently of one another, an integer ranging from 1 to 4, &#x2014;X denotes an oxygen atom or an N&#x2014;R3 group, &#x2014;R1 and R3 denote, independently of one another, a linear or branched Cto Calkyl group, and &#x2014;R2 denotes a residue of a molecule of therapeutic or diagnostic interest, or pharmaceutically acceptable salts of said derivatives, and also the method for the preparation thereof and the therapeutic or diagnostic use thereof. 

Hydroxy-bisphosphonic acid derivatives as vector targeting bone tissue

Growing community of inventors

Nantes, France

Jacques Lebreton